Hyperoxaluria News and Research

RSS

Lumasiran shows efficacy and acceptable safety in patients with PH1 and advanced kidney disease

In patients with PH1 and advanced kidney disease, including patients on hemodialysis, use of Lumasiran shows substantial reductions in plasma oxalate levels with acceptable safety.

14 Jul 2022

Results of high-impact clinical trials could affect kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online at ASN Kidney Week 2021 November 4–November 7.

7 Nov 2021

Drug offers hope for patients with primary hyperoxaluria type 1

Primary hyperoxaluria type 1 (PH1) is an autosomal recessive inherited disorder that begins in childhood and adolescence.

8 Jun 2020

Polycystic kidney disease may be preventable

Kidney failure is a lifelong burden in hundreds of thousands of people who need to be treated either by dialysis or a kidney transplant. Both procedures significantly increase the cost of healthcare and reduce the quality of life.

26 Aug 2019

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

Captozyme begins cross-over study of Nephure oxalate reducing enzyme

Captozyme, Inc. announced today that it is initiating a prospective double-blind, randomized, placebo controlled, cross-over study, with Nephure, an oxalate reducing enzyme, to determine the extent to which Nephure vs. placebo reduces urinary oxalate excretion (mg/24 hour) in healthy subjects who are provided a controlled diet.

12 Jul 2018

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.

8 Jun 2018

UCLA research may lead to novel treatment for PH1

Research by UCLA biochemists may lead to a new treatment - or even a cure - for PH1, a rare and potentially deadly genetic kidney disease that afflicts children. Their findings also may provide important insights into treatments for Parkinson's disease, Alzheimer's disease and other degenerative diseases.

27 Sep 2014

Oxabact now recognized as potential treatment for Short Bowel Syndrome

SBS is a highly disabling malabsorptive condition. SBS is associated with significant morbidity and mortality, reduced quality of life and high healthcare costs.

23 Sep 2014

OxThera granted new patents for treatment of hyperoxaluria

OxThera AB announced today that it has been granted two new US patents and one new Australian patent during the last year.

15 May 2014

OxThera announces initiation of Oxabact clinical study in Primary Hyperoxaluria

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.

8 Jan 2014

OxThera granted Japanese patents for treating oxalate-related disease

OxThera AB has been granted three Japanese patents during 2012 and 2013. The patents will secure the pharmaceutical composition and the method for treating and preventing oxalate-related disease with micro-organisms and enzymes and will further strengthen the Company's patent estate for this unmet medical need.

4 Jun 2013

Althea provides Allena exclusive worldwide rights to broad hyperoxaluria portfolio

Allena Pharmaceuticals, Inc., and Althea Technologies today announced a licensing agreement under which Allena has obtained the exclusive worldwide rights to Althea's broad hyperoxaluria portfolio including product patents, regulatory information and development data related to oxalate degrading enzymes.

29 Mar 2012

Gastric bypass linked to greater risk of kidney stones

Morbidly obese patients who undergo a particular type of gastric bypass surgery called Roux-en-Y gastric bypass (RYGB) are at an increased risk of developing kidney stones - small, pebble-like deposits that can result in severe pain and require an operation to remove them - earlier than previously thought. These stones develop in patients within only a few months following the procedure rather than several months to years, according to research published in the June issue of the Journal of the American College of Surgeons.

26 Jun 2008

AUA podium session on stone disease

2-phase randomized crossover study on a constant diet with calcium carbonate supplementation at 250 mg 4 times daily.

13 Jun 2006

Pharmacogenomics used to treat inherited kidney disorder of children

Mayo Clinic researchers have used pharmacogenomics to develop a test and treatment for an inherited kidney disorder that can cause organ failure in children and young adults.

4 May 2005